




13

Mailing Date: January 20, 2004
Client: 71758
Inventors: Jin-an JIAO, et al.
Serial No.: 09/990,586
Filing Date: November 21, 2001
Attorney/Sec: PFC/RLB/pb
Docket No.: 46943-CIP2
Patent No.:
Grant Date:
The dating stamp of the Patent and Trademark Office hereon will be taken as the date of filing of:
Supplemental Information Disclosure Statement; Form PTO-1449 (one sheet); copy of single
reference listed thereon; Certificate of Mailing.



Due Date: N/A



Attorney Docket No. 46943-CIP2 (71758)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Jin-an JIAO, et al.

U.S.S.N.: 09/990,586

Group Art Unit: 1644

FILED: November 21, 2001

Examiner: Not yet assigned

FOR: ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND METHODS
OF USE THEREOF

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on **January 20, 2004**.

By: Patricia A. Barnes
Patricia A. Barnes

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Date: January 20, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

a. ☒

Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

a. ☒ Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).

b. ☐ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:

c. ☐ The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)

(check one box)

a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.

b. ☐ within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.

c. ☒ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or,

if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

- a. ☐ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).
or
- b. ☐ See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

- a. ☐ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
- c. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

☐

Please charge Deposit Account No. 04-1105 in the amount of \$180.00 for the above-indicated fee. A triplicate copy of this paper is attached.


☒

No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.

Respectfully submitted,


Date: January 20, 2004



Robert L. Buchanan, (Reg. No. 40,927]
EDWARDS & ANGELL, LLP.
P. O. Box 9169
Boston, MA 02209
Tel: (617) 439-4444
Fax Nos.: (617) 439-4170 / 7748

Customer No.: 21874

#430243

<div style="text-align: center;">  <p>INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> </div>	Docket Number (Optional) 46943-CIP2 (7)	Application Number 09/990,586
	Applicant(s) Jin-an JIAO, et al.	
	Filing Date November 21, 2001	Group Art Unit 1644

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,593,291 B1	07/15/2003	Green et al.	514/2	514/21	10/14/1999


FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RLB



Mailing Date: August 19, 2004 Attorney/Sec: PFC/RLB/pb
Client: 71758 Docket No.: 46943-CIP2
Inventors: Jin-an JIAO, et al.
Serial No.: 09/990,586 Patent No.:
Filing Date: November 21, 2001 Grant Date:


The dating stamp of the Patent and Trademark Office hereon will be taken as the date of filing of:
Second Supplemental Information Disclosure Statement; Form PTO-1449 (one sheet); One copy of
each reference listed thereon; Check in the amount of \$180.00 (fee for IDS); Certificate of Express
Mail.

Express Mail Label No. EV438994483US



Due Date: N/A

SB



Attorney Docket No. 46943-CIP2 (71758)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Jin-an JIAO, et al.

U.S.S.N.: **09/990,586**

Group Art Unit: 1644

FILED: November 21, 2001

Examiner: M. Haddad

FOR: ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND
METHODS OF USE THEREOF

CERTIFICATE OF EXPRESS MAIL

I, Patricia A. Barnes, hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office To Addressee" service, Label No. EV438994483US in an envelope addressed to Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on August 19, 2004.

By: Patricia A. Barnes
Patricia A. Barnes

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE)**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Date August 19, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- a. ☒ Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

- a. ☒ Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).
- b. ☐ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
- c. ☐ The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)
(check one box)

- a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.
- b. ☐ within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.

- c. ☐ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$1800.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

- a. ☒ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p). A check in the amount of \$180.00 is enclosed.
or
b. ☐ See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

- a. ☐ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
- c. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was

known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

- ☐ Please charge Deposit Account No. 04-1105 in the amount of \$180.00 for the above-indicated fee. A triplicate copy of this paper is attached.
- ☐ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.


Respectfully submitted,

Date: 19 April 2004



Robert L. Buchanan, (Reg. No. 40,927)
EDWARDS & ANGELL, LLP
P. O. Box 55874
Boston, MA 02205
Tel: (617) 439-4444
Fax Nos.: (617) 439-4170 / 7748
Customer No.: 21874

#454792



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

DOCKET NO:

46943-CIP2 (71758)

SERIAL NO.:

09/990,586

APPLICANT(S): Jin-an JIAO, et al.

FILING DATE:

November 21, 2001

GROUP NO.:

1644

UNITED STATES PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,816,567	3/28/89	Cabilly et al.	530/387	435/68	4/8/83
	AB	5,122,458	6/16/92	Post et al.	435/69.1	435/69.2	1/11/89
	AC	5,168,062	12/1/92	Stinski	435/240.2	435/320.1	9/10/90
	AD	5,385,839	1/31/95	Stinski	435/240.2	435/69.1	6/17/92
	AE	5,879,677	3/9/99	del Zoppo	424/145.1	424/139.1	1/13/95
	AF	6,001,978	12/14/99	Edgington et al.	530/391.3	424/139.1	4/22/97
	AG	6,054,297	4/25/2000	Carter et al.	435/69.6	435/69.7	5/9/95
	AH	6,331,415 B1	12/18/01	Cabilly et al.	435/69.6	435/69.1	6/10/88
	AI	6,677,436 B1	1/13/04	Sato et al.	530/387.3	530/387.9	4/2/99
	AJ	2003/0119075 A1	6/26/03	Kirchhofer et al.	435/7.21	424/145.1	3/8/01
	AK	2003/0087372 A1	5/8/03	DelaCruz et al.	435/69.1	435/325	6/11/02
	AL	5,889,157	3/30/99	Pastan et al.	530/387.1	530/387.3	10/28/94
	AM	6,610,293 B1	8/26/03	Fischer et al.	424/133.1	530/387.3	6/15/98
	AN	5,530,101	6/25/96	Queen et al.	530/387.3	530/387.1	12/19/90

FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
	BA	EP 1 069 185 A1	17/01/2001	Europe			Y

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)



CA	I. Benhar, et al., Rapid Humanization of the Fv of Monoclonal Antibody B3 B γ Using Framework Exchange of the Recombinant Immunotoxin B3(Fv)-PE38, Proc. Natl. Acad. Sci. USA, December 1994, Vol. 91, pages 12051-12055.
CB	J. R. Couto, et al., Anti-BA46 Monoclonal Antibody Mc3: Humanization Using a Novel Positional Consensus and in Vivo and in Vitro Characterization, Cancer Research, April 15, 1995, Vol. 55, pages 1717-1722.

#454800

RLB




Mailing Date: August 23, 2004 Attorney/Sec: PFC/RLB/pb
Client: 71758 Docket No.: 46943-CIP2
Inventors: Jin-an JIAO, et al.
Serial No.: 09/990,586 Patent No.:
Filing Date: November 21, 2001 Grant Date:
The dating stamp of the Patent and Trademark Office hereon will be taken as the date of filing of:
LETTER; Copies of Form PTO-1449 (four sheets); Certificate of Express Mail.
Label No. EV438994545US



Due Date: N/A

SB



Attorney Docket No. 46943-CIP2 (71758)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Jin-an JIAO, et al.

U.S.S.N.: 09/990,586

Group Art Unit: 1644

FILED: November 21, 2001

Examiner: M. Haddad

FOR: ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND
METHODS OF USE THEREOF

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF EXPRESS MAIL

I, Patricia A. Barnes, hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office To Addressee" service, **Label No. EV438994545US** in an envelope addressed to Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on **August 23, 2004**.

By: *Patricia A. Barnes*
Patricia A. Barnes

Sir:

LETTER

We enclose herewith Form PTO-1449 sheets listing references for the Examiner's consideration in connection with the above-identified application. Copies of the references were previously submitted in related application USSN 10/230,880, filed August 29, 2002 (divisional of U. S. Patent No. 5,986,065).


If the Examiner should require copies of any of the references, they will be supplied on request.

USSN 09/990,586
Jin-an JIAO, et al.
LETTER
Pg. 2


Although it is not believed that any fee is needed to consider this Letter, the USPTO is authorized to charge deposit account number **04-1105** should such fee be deemed necessary.

Respectfully submitted,

Date: 23 August 2024


Robert L. Buchanan
Registration No. 40,927
EDWARDS & ANGELL, LLP
P. O. Box 55874
Boston, MA 02205
Tel. (617) 439-4444
Fax: (617) 439-4170 / 7748
Customer No.: 21874

#455704



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

DOCKET NO:

46943-CIP2 (71758)

SERIAL NO.:

09/990,586

APPLICANT(S): Jin-an JIAO, et al.

FILING DATE:

November 21, 2001

GROUP NO.:

1644

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL S		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT
	AA	6,333,167 B1	12/25/01	Quinet et al.	435	23	03/10/00
	AB	6,245,884 B1	06/12/01	Hook	530	300	10/16/98
	AC	6,117,639	09/12/00	Germann et al.	435	6	08/31/98
	AD	5,958,713	09/28/99	Thastrup et al.	435	7.4	03/14/97
	AE	5,861,267	01/19/99	Su	435	23	05/1/95
	AF	5,171,662	12/15/92	Sharma	435	5	04/04/91
	AG	4,644,055	02/17/87	Kettner et al.	530	330	12/17/84
	AH	2002/0025508 A1	02/28/02	Fechteler et al.	435	4	01/05/01

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO YES/NO
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

CA	Boulianne, et al., "Production of functional chimaeric mouse/human antibody", Nature, Vol. 317, pp. 643-646, December 13, 1984.
CB	Bruggemann, et al., "The Immunogenicity of Chimeric Antibodies", J. Exp. Med., [Vol.] 170, pp 2153-2157, December 1989.

EXAMINER:


DATE:

	CC	Carter, et al., "Humanization of an anti-p185 ^{HER2} antibody for human cancer therapy", Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 4285-4289, May, 1992.
	CD	Casipit, et al., "Improving the binding affinity of an antibody using molecular modeling and sit directed mutagenesis", Protein Science, [Vol. 7], pp. 1671-1680, 1998.
	CE	Co, et al., "Humanized antibodies for antiviral therapy", Proc. Natl. Acad. Sci. USA, Vol. 88, pp 2869-2873, April 1991.
	CF	Couto, et al., "Designing Human Consensus Antibodies with Minimal Positional Templates", [Cancer Research (Supp.)], [Vol. 55], pp. 5973-5977, December 1, 1995
	CG	Jager, et al., "Current Status of Cancer Immunodetection With Radiolabeled Human Monoclonal Antibodies", Seminars in Nuclear Medicine, Vol. XXIII, No. 2, pp. 165-179, 1993.
	CH	Faber, et al., "A Novel Method to Determine the Topology of Peroxisomal Membrane Proteins <i>in Vivo</i> Using the Tobacco Etch Virus Protease", The Journal of Biological Chemistry, Vol. 276, No. 39, pp. 36501-36507, September 28, 2001.
	CI	Foote, et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops", J. Mol. Biol., Vol. 224, pp. 487-499. (1992).
	CJ	Gorman, et al., "Reshaping a therapeutic CD4 antibody", Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 4181-4185, May 1991.
	CK	Griffiths, et al., "Human anti-self antibodies with high specificity from phage display libraries", The EMBO Journal, Vol. 12, No. 2, pp. 725-734, 1993.
	CL	Hanes, et al., "Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display", Nature Biotechnology, Vol. 18, pp. 1287-1292, December 2000.
	CM	Kao, et al., "Chimeric Antibodies with Anti-Dextran-Derived Complementarity-Determining Regions and Anti-p-Azophenylarsonate-Derived Framework Regions", The Journal of Immunology, Vol. 151, pp. 1968-1979, August 15, 1993.
	CN	Knappik, et al., "Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides", J. Mol. Biol., Vol. 296, pp. 57-86, 2000.
	CO	Leong, et al., "Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation", Cytokine, Vol. 16, No. 3, pp. 106-119, 2001.
	CP	LoBuglio, et al., "Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response", Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 4220-4224, June 1989.
	CQ	Mateo, et al., "Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity", Immunotechnology, [Vol. 3], pp. 71-81, 1997
	CR	Morrison, et al., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains", Proc. Natl. Acad. Sci. USA, Vol. 81, pp. 6851-6855, November 1984.
	CS	Morrison, et al., "Genetically Engineered Antibody Molecules", Advances in Immunology, Vol. 44, pp. 65-93.
	CT	Padlan, "On the Nature of Antibody Combining Sites: Unusual Structural Features That May Confer on These Sites an Enhanced Capacity for Binding Ligands", Proteins, [Vol. 7], pp. 112-124, 1990.
	CU	Padlan, "A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties", Mol. Immun., Vol. 28, No. 4/5, pp.489-498, 1991.
EXAMINER:		DATE:

		while preserving their ligand-binding properties", Molecular Immunology, Vol. 28, No. 4/5, pp. 489-498, 1991.
	CV	Padlan, "Anatomy of the antibody molecule", Molecular Immunology, Vol. 31, No. 3, pp. 169-217, 1994.
	CW	Queen, et al., "Cell-Type Specific Regulation of a <i>k</i> Immunoglobulin Gene by Promoter and Enhancer Elements", Immunological Reviews, No. 89, pp. 49-68, 1986.
	CX	Queen, et al., "A humanized antibody that binds to the interleukin 2 receptor", Proc. Natl. Aca Sci. USA, Vol. 86, pp. 10029-10033, December 1989.
	CY	Reichert, "Monoclonal antibodies in the clinic", Nature Biotechnology, Vol. 19, pp. 819-822, September 2001.
	CZ	Riechmann, et al., "Reshaping human antibodies for therapy", Nature, Vol. 332, pp. 323-327, March 24, 1988.
	CAA	Robertson, "Genentech awarded critical antibody patent", Nature Biotechnology, Vol. 20, p. 108, February 2002.
	CBB	Roguska, et al., "Humanization of murine monoclonal antibodies through variable domain resurfacing", Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 969-973, February 1994.
	CCC	Roguska, et al., "A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing", Protein Engineering, Vol. 9, No. 10, pp. 895-904, 1996.
	CDD	Saldanha, et al., "A single backmutation in the human <i>k</i> IV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in <i>cos</i> cells", Molecular Immunology, [Vol. 36], pp. 709-719, 1999.
	CEE	Shearman, et al., "Construction, expression and characterization of humanized antibodies directed against the human α/β T cell receptor", The Journal of Immunology, Vol. 147, pp. 4366-4373, December 15, 1991.
	CFF	Tan, et al., "Superhumanized" Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD28", The Journal of Immunology, [Vol. 169], pp. 1119-1125, 2002.
	CGG	Tempest, et al., "Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection <i>in vivo</i> ", Bio/Technology, Vol. 9, pp. 266-271, March 1991.
	CHH	Teng, et al., "Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production", Proc. Natl. Acad. Sci. USA, Vol. 80, pp. 7308-7312, December 1983.
	CII	Tomizuka, et al., "Double trans-chromosomal mice: Maintenance of two individual human chromosome fragments containing Ig heavy and <i>k</i> loci and expression of fully human antibodies", PNAS, Vol. 97, No. 2, pp. 722-727, January 18, 2000.
	CJJ	Vaughan, et al., "Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library", Nature Biotechnology, Vol. 14, pp. 309-314, March 1996.
	CKK	Verhoeyen, et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity", Science, Vol. 239, pp. 1534-1536, March 25, 1988.

EXAMINER:

DATE:



FORM PTO-1449				DOCKET NO: 46943-CIP2 (71758)		SERIAL NO.: 09/990,586	
INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Jin-an JIAO, et al.			
				FILING DATE: November 21, 2001		GROUP NO.: 1644	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,997,867	12/07/99	Waldmann et al.	424	154.1	6/5/95
	AB	5,985,279	11/16/99	Waldmann et al.	424	144.1	7/15/92
	AC	5,766,886	6/16/98	Studnicka et al.	435	70.21	12/14/92
	AD	5,693,762	12/2/97	Queen et al.	530	387.3	6/7/95
	AE	5,225,539	7/6/93	Winter	530	387.3	10/25/91
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATI ON YES/NO
	BA						
	BB						
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	CA	Presta, et al., "Generation of a Humanized, High Affinity Anti-tissue Factor Antibody for Use as a Novel Antithrombotic Therapeutic", Thromb Haemost, Vol. 85, pp.379-89, 2001.					
	CB	Saldanha, J., "Choice of Human Frameworks", National Institute for Medical Research, 2002.					
	CC	Robertson, D., "Genentech awarded critical antibody patent", Nature Biotechnology, Vol. 20, pp. 108, 2002.					
EXAMINER:					DATE:		